Cerevel Therapeutics Stock Price, News & Analysis (NASDAQ:CERE) $26.00 +0.07 (+0.27%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$25.28▼$26.1550-Day Range$20.27▼$26.3652-Week Range$19.59▼$35.98Volume1.60 million shsAverage Volume675,409 shsMarket Capitalization$4.69 billionP/E RatioN/ADividend YieldN/APrice Target$32.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial Media Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside24.4% Upside$32.33 Price TargetShort InterestBearish9.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.10Based on 2 Articles This WeekInsider TradingAcquiring Shares$145 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.52) to ($2.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.61 out of 5 starsMedical Sector858th out of 953 stocksPharmaceutical Preparations Industry416th out of 447 stocks 2.3 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.33, Cerevel Therapeutics has a forecasted upside of 24.4% from its current price of $26.00.Amount of Analyst CoverageCerevel Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.73% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Cerevel Therapeutics has recently decreased by 1.56%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 2.3 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for CERE on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have bought 5,139.49% more of their company's stock than they have sold. Specifically, they have bought $144,999,977.00 in company stock and sold $2,767,443.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.52) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -10.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -10.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 17.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comCerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s DiseaseNovember 22, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Amylyx Pharmaceuticals Inc (AMLX)December 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 20, 2023 | benzinga.comCerevel Therapeutics Hldg Stock (NASDAQ:CERE) Dividends: History, Yield and DatesNovember 17, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Akebia Therapeutics (AKBA)November 17, 2023 | finance.yahoo.comInsider Sell Alert: Director N Coles Sells 22,824 Shares of Cerevel Therapeutics Holdings Inc (CERE)November 15, 2023 | markets.businessinsider.comHold Rating Maintained for Cerevel Therapeutics: Potential Catalysts, High Risk Trials, and Financial Health in FocusNovember 7, 2023 | msn.comWall Street Analysts Think Cerevel Therapeutics Holdings, Inc. (CERE) Could Surge 27.31%: Read This Before Placing a BetDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cerevel Therapeutics Holdings (CERE), Genmab (GMAB) and BioMarin Pharmaceutical (BMRN)November 6, 2023 | realmoney.thestreet.comThis Mid-Cap Biotech Stock Could Rise More Than 40% From HereNovember 4, 2023 | finance.yahoo.comDirector Deval Patrick Sells 30,130 Shares of Cerevel Therapeutics Holdings Inc (CERE)November 2, 2023 | finance.yahoo.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | msn.comCerevel Therapeutics: High Standards And Development Burden Poses Reflexivity RisksNovember 1, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX), Omega Therapeutics (OMGA) and Karuna Therapeutics (KRTX)November 1, 2023 | seekingalpha.comCerevel Therapeutics Holdings, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 1, 2023 | msn.comCerevel Therapeutics GAAP EPS of -$0.61 beats by $0.04November 1, 2023 | finance.yahoo.comCerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 1, 2023 | finance.yahoo.comCerevel Therapeutics Holdings Inc (CERE) Reports Q3 2023 Financial ResultsOctober 20, 2023 | finance.yahoo.comBain Capital Investors LLC Acquires Additional Shares in Cerevel Therapeutics Holdings IncOctober 19, 2023 | benzinga.comDirector of Cerevel Therapeutics Hldg Purchased $125.00M In StockOctober 19, 2023 | benzinga.comCerevel Therapeutics Hldg Insider Trades Send a SignalOctober 19, 2023 | msn.comCerevel Therapeutics says Perceptive Advisors buys 876.8K sharesOctober 13, 2023 | finance.yahoo.comCerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023October 11, 2023 | finance.yahoo.comCerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common StockOctober 11, 2023 | seekingalpha.comCerevel Therapeutics starts public offering of $400M of sharesOctober 10, 2023 | tmcnet.comPacira BioSciences Appoints Four New Independent Directors to its Board of DirectorsSee More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels SectorMedical Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees321Year FoundedN/APrice Target and Rating Average Stock Price Target$32.33 High Stock Price Target$46.00 Low Stock Price Target$22.00 Potential Upside/Downside+24.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-351,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.72% Return on Assets-42.90% Debt Debt-to-Equity Ratio1.23 Current Ratio8.72 Quick Ratio8.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book17.22Miscellaneous Outstanding Shares180,280,000Free Float171,084,000Market Cap$4.69 billion OptionableNot Optionable Beta1.38 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 63)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 50)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 54)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 62)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 54)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 41)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 38)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 64)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 52)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsImmunoGenNASDAQ:IMGNBlueprint MedicinesNASDAQ:BPMCPerrigoNYSE:PRGOBridgeBio PharmaNASDAQ:BBIOMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 47,760 shares on 12/1/2023Ownership: 0.026%American Century Companies Inc.Sold 1,504 shares on 11/30/2023Ownership: 0.171%Deutsche Bank AGBought 4,599 shares on 11/24/2023Ownership: 0.019%Graham Capital Management L.P.Bought 31,506 shares on 11/22/2023Ownership: 0.023%Polar Capital Holdings PlcSold 900,000 shares on 11/22/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CERE shares. View CERE analyst ratings or view top-rated stocks. What is Cerevel Therapeutics' stock price target for 2024? 9 Wall Street research analysts have issued 12 month price objectives for Cerevel Therapeutics' shares. Their CERE share price targets range from $22.00 to $46.00. On average, they predict the company's share price to reach $32.33 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts. How have CERE shares performed in 2023? Cerevel Therapeutics' stock was trading at $31.54 at the beginning of 2023. Since then, CERE stock has decreased by 17.6% and is now trading at $26.00. View the best growth stocks for 2023 here. When is Cerevel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our CERE earnings forecast. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.02. During the same period in the previous year, the company posted ($0.66) earnings per share. What ETFs hold Cerevel Therapeutics' stock? ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN) and Principal Healthcare Innovators ETF (BTEC).Harbor Health Care ETF (MEDI). What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.10%), Rock Springs Capital Management LP (1.40%), Adage Capital Partners GP L.L.C. (0.84%), Westfield Capital Management Co. LP (0.54%), Affinity Asset Advisors LLC (0.38%) and Avidity Partners Management LP (0.36%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick, Gabrielle Sulzberger, John Renger, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc and Ronald C Renaud Jr. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CERE) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.